What was ARROWHEAD PHARMACEUTICALS, INC.'s revenue in Q1 FY2026?

ARROWHEAD PHARMACEUTICALS, INC. reported total revenue of $264.0M in Q1 FY2026.

What was ARROWHEAD PHARMACEUTICALS, INC.'s net profit in Q1 FY2026?

ARROWHEAD PHARMACEUTICALS, INC. reported net profit of $30.8M in Q1 FY2026, a net margin of 11.7%.

What were ARROWHEAD PHARMACEUTICALS, INC.'s margins in Q1 FY2026?

ARROWHEAD PHARMACEUTICALS, INC. had operating margin of 15.5% in Q1 FY2026.

What was ARROWHEAD PHARMACEUTICALS, INC.'s EPS in Q1 FY2026?

ARROWHEAD PHARMACEUTICALS, INC. reported diluted EPS of $0.22 in Q1 FY2026.

ARROWHEAD PHARMACEUTICALS, INC.ARWREarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Deep Analysis

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

Q1 2026

Revenue

$264.0M

Gross Profit

N/A

Operating Profit

$40.8M

Net Profit

$30.8M

Gross Margin

N/A

Operating Margin

15.5%

Net Margin

11.7%

YoY Growth

10461.3%

EPS

$0.22

ARROWHEAD PHARMACEUTICALS, INC. Q1 FY2026 Financial Summary

ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $264.0M (up 10461.3% YoY) for Q1 FY2026, with a net profit of $30.8M (up 117.8% YoY) (11.7% margin).

Key Financial Metrics

Total Revenue	$264.0M
Net Profit	$30.8M
Gross Margin	N/A
Operating Margin	15.5%
Report Period	Q1 FY2026

Income Statement

	Q1 2026
Revenue	$264.0M
YoY Growth	10461.3%

Balance Sheet

	Q1 2026
Assets	$1.60B
Liabilities	N/A
Equity	$568.4M

Cash Flow

	Q1 2026
Operating CF	$13.5M